Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7218555 | 0.79 | HDAC3 (0.37) | MAPK14HDAC6SMN1; SMN2 | |
| SCHEMBL7213350 | 0.78 | KMT2A (0.43) | KMT2AMEN1MLYCDHDAC6NPC1 | |
| SCHEMBL7213367 | 0.78 | KMT2A (0.43) | KMT2AMEN1MLYCDHDAC6NPC1 | |
| SCHEMBL7218616 | 0.76 | KMT2A (0.47) | KMT2AMEN1NPC1HPGDSMN1; SMN2 | |
| SCHEMBL7219875 | 0.75 | KMT2A (0.41) | KMT2AMEN1MLYCDHDAC6NPC1 | |
| SCHEMBL7218637 | 0.74 | DDX3X (0.44) | MAPK14HDAC6 | |
| SCHEMBL7215115 | 0.74 | ALDH1A1 (0.39) | KMT2AMEN1HDAC6NPC1HPGD | |
| SCHEMBL7219299 | 0.74 | MAPK14 (0.37) | MAPK14 | |
| SCHEMBL13614176 | 0.73 | RIPK1 (0.47) | MAPK14KMT2AMEN1MLYCDHPGD | |
| SCHEMBL7213379 | 0.73 | NPC1 (0.45) | KMT2AMEN1NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624309-B1 | Administering 4-heterocyclicbenzamide derivative | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | LLOYD JOHN (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | SCN1A, SCN1B, NR0B1 | MAPK14 2213/4885KMT2A 2962/4885MEN1 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.